A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

The purpose of this study is to evaluate the safety and efficacy of lisocabtagene maraleucel (Breyanzi/liso-cel/BMS-986387) in adults as first-line treatment in transplant-ineligible Primary Central Nervous System Lymphoma (PCNSL).

Trial Details

NCT ID
NCT07015242
Phase
PHASE2
Sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Rituximab
  • Methotrexate
  • Procarbazine
  • Temozolomide
  • Liso-cel
  • Fludarabine
Locations (sample)
  • Aurora, Colorado, United States|39.72943,-104.83192
  • Tampa, Florida, United States|27.94752,-82.45843
  • Chicago, Illinois, United States|41.85003,-87.65005
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • St Louis, Missouri, United States|38.62727,-90.19789

Key Eligibility Criteria

  • Participant must be 18 years or older at the time of signing the informed consent form (ICF).
  • Histologically confirmed primary central nervous system (CNS) lymphoma (PCNSL) prior to screening, as assessed by local pathology.
  • Transplant-ineligible based on physician's assessment and meeting at least one of the following criteria: age ≥65 years or HCT-CI (Hematopoietic Ce…
  • Participant must be suitable, per investigator, to receive a high dose methotrexate (HD-MTX) based treatment regimen.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →